Fredun Pharmaceuticals Share Price

  • 787.50-9.70 (-1.21%)
  • Volume: 3,912
BSE
  • Closed
  • Last Updated On: 29 Aug, 2024, 03:50 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • TECHNICALS
  • COMPARE
Loading...

Fredun Pharmaceuticals ...

  • 787.50-9.70 (-1.21%)
  • Volume: 3,912
Advertisment

Fredun Pharma share price insights

View All

  • Company delivered ROE of 12.86% in year ending Mar 31, 2024 outperforming its 5 year avg. of 9.91%. (Source: Standalone Financials)

  • Company witnessed QoQ revenue decline of 33.23%, which is lowest in the last 3 years. (Source: Standalone Financials)

  • Stock gave a 3 year return of 107.24% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)

  • Company has spent 3.91% of its operating revenues towards interest expenses and 3.58% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)

  • Fredun Pharmaceuticals Ltd. share price moved down by -1.21% from its previous close of Rs 797.20. Fredun Pharmaceuticals Ltd. stock last traded price is 787.50

    Share PriceValue
    Today/Current/Last-787.50
    Previous Day-797.20

InsightsFredun Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		21.33
    EPS - TTM
    (₹)    		36.92
    MCap
    (₹ Cr.)    		370.06
    Sectoral MCap Rank
    		103
    PB Ratio
    (x)    		3.07
    Div Yield
    (%)    		0.09
    Face Value
    (₹)    		10.00
    Beta

    Beta

    1 Month0.09
    3 Months0.38
    6 Months0.68
    1 Year0.96
    3 Years0.49

    		0.09
    VWAP
    (₹)    		787.30
    52W H/L
    (₹)
    1,054.00 / 650.00

    Fredun Pharma Share Price Returns

    1 Day-1.21%
    1 Week-1.06%
    1 Month-9.99%
    3 Months-1.92%
    1 Year-17.66%
    3 Years107.24%
    5 Years263.15%

    ET Stock ScreenersTop Score Companies

    Check whether Fredun Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Fredun Pharma News & Analysis

    View all Fredun Pharma Share News & Announcements

    Fredun Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Fredun Pharma Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Fredun Pharma Financials

    • Income (P&L)

    • Balance Sheet

    • Cash Flow

    • Ratios

    • Insights

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 33.23%, which is lowest in the last 3 years. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent 3.91% of its operating revenues towards interest expenses and 3.58% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
      Quarterly | AnnualJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
      Total Income78.81118.0387.0181.9962.05
      Total Income Growth (%)-33.2335.666.1332.14-22.25
      Total Expenses69.38107.8277.4873.3255.35
      Total Expenses Growth (%)-35.6539.175.6832.45-18.89
      EBIT9.4310.219.538.676.69
      EBIT Growth (%)-7.637.139.9429.53-42.11
      Profit after Tax (PAT)4.135.064.223.942.40
      PAT Growth (%)-18.4219.877.2963.89-38.28
      EBIT Margin (%)11.978.6510.9510.5710.79
      Net Profit Margin (%)5.244.294.854.803.87
      Basic EPS (₹)8.7910.778.998.405.24
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue349.07276.50226.09135.29113.29
      Total Revenue Growth (%)26.2522.3067.1119.4216.31
      Total Expenses327.62258.99217.49130.92110.79
      Total Expenses Growth (%)26.5019.0866.1218.1721.43
      Profit after Tax (PAT)15.6210.816.342.011.90
      PAT Growth (%)44.5770.58214.465.93-57.36
      Operating Profit Margin (%)10.059.755.916.376.12
      Net Profit Margin (%)4.473.932.821.501.68
      Basic EPS (₹)33.3224.1311.285.054.77

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Profit & Loss Statement are available.

    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets307.60257.28186.99161.62133.16
      Total Assets Growth (%)19.5637.5915.7021.3726.93
      Total Liabilities186.13160.90118.93118.5591.84
      Total Liabilities Growth (%)15.6835.290.3229.0839.32
      Total Equity121.4796.3868.0643.0741.32
      Total Equity Growth (%)26.0341.6158.024.245.98
      Current Ratio (x)1.472.042.071.501.30
      Total Debt to Equity (x)0.870.900.780.920.84
      Contingent Liabilities0.00----

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Balance Sheet are available.

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 7.64 cr for investing activities which is an YoY decrease of 18.77%. (Source: Standalone Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities-0.44-14.41-2.380.17-10.61
      Net Cash used in Investing Activities-7.64-9.40-4.13-1.39-1.49
      Net Cash flow from Financing Activities5.9925.187.47-0.7113.70
      Net Cash Flow-2.081.360.96-1.931.59
      Closing Cash & Cash Equivalent1.073.442.091.133.06
      Closing Cash & Cash Equivalent Growth (%)-68.8064.7284.85-63.12108.56
      Total Debt/ CFO (x)-240.51-6.01-22.17233.27-3.29

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Cash Flow Statement are available.

    • Insights

      • ROE Outperforming 5 Year Average

        Company delivered ROE of 12.86% in year ending Mar 31, 2024 outperforming its 5 year avg. of 9.91%. (Source: Standalone Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)12.8611.219.304.674.60
      Return on Capital Employed (%)26.3617.7211.7111.3512.47
      Return on Assets (%)5.074.203.381.241.42
      Interest Coverage Ratio (x)2.853.193.302.531.99
      Asset Turnover Ratio (x)1.241.241.2982.8484.68
      Price to Earnings (x)21.6032.6864.1092.5924.45
      Price to Book (x)2.773.665.964.291.13
      EV/EBITDA (x)11.3414.7129.5921.218.92
      EBITDA Margin (%)11.1410.776.877.867.79

      No reported Financial Ratios are available.

    Financial InsightsFredun Pharma

    • Income (P&L)
    • Cash Flow
    • Ratios

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 33.23%, which is lowest in the last 3 years. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent 3.91% of its operating revenues towards interest expenses and 3.58% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)

      • Decrease in Cash from Investing

        Company has used Rs 7.64 cr for investing activities which is an YoY decrease of 18.77%. (Source: Standalone Financials)

      • ROE Outperforming 5 Year Average

        Company delivered ROE of 12.86% in year ending Mar 31, 2024 outperforming its 5 year avg. of 9.91%. (Source: Standalone Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Fredun Pharma Peer Comparison

    • Fredun Pharma Stock Performance

    • Ratio Performance

      • CHART
      • TABLE

      Insights

      • Stock Returns vs Nifty Smallcap 100

        Stock gave a 3 year return of 107.24% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)

      • Stock Returns vs Nifty Pharma

        Stock generated 107.24% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Insights

          • Stock Returns vs Nifty Smallcap 100

            Stock gave a 3 year return of 109.03% as compared to Nifty Smallcap 100 which gave a return of 92.43%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 109.03% return as compared to Nifty Pharma which gave investors 64.81% return over 3 year time period. (as of last trading session)

          Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Fredun Pharma21.333.0512.8626.365.0736.7210.054.4733.321.470.87-240.51
          Lyka Labs600.787.74-3.653.66-1.588.573.92-2.35-0.791.350.8432.36
          Jenburkt Pharma17.983.4817.9223.8315.738.7924.9618.2958.866.700.000.00
          Ambalal Sarabhai42.663.624.148.862.27-1.787.554.830.741.160.339.56
          SMS Lifesciences Ind24.852.295.148.132.324.986.532.0630.081.070.554.02
          Add More
          Annual Ratios (%)

          Choose from Peers

          • POCL Enterprises
          • Zenotech Lab
          • Medico Remedies
          • Panchsheel Org
          • Sanjivani paranteral

          Choose from Stocks

            See All Parameters

          Peers InsightsFredun Pharma

          • Stock Returns vs Nifty Smallcap 100

            Stock gave a 3 year return of 107.24% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 107.24% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)

          Do you find these insights useful?

          • hate it

          • meh

          • love it

          Fredun Pharma Shareholding Pattern

          • QOQ Change

          • Total Shareholdings

          • Loading...
            Showing Fredun Pharma Shareholding as on 30 Jun 2024
            Category30 Jun 202431 Mar 202430 Sep 202330 Jun 2023
            Promoters49.1749.1749.3149.62
            Pledge0.000.000.000.00
            FII0.000.000.000.00
            DII0.000.000.000.00
            Mutual Funds0.000.000.000.00
            Others50.8350.8350.6950.38
          • Showing Shareholding as on 30 Jun 2024
            CategoryNo. of SharesPercentage% Change QoQ
            Promoters23,10,38549.17 %0.00
            Pledge00.00 %0.00
            Others23,88,77750.83 %0.00

          MF Ownership

          MF Ownership details are not available.

          Top Searches:

          Fredun Pharma News Fredun Pharma Quarterly Results Fredun Pharma Dividend Fredun Pharma Q1 ResultsFredun Pharma Q2 ResultsFredun Pharma Q3 ResultsFredun Pharma Q4 Results

          Corporate Actions

          • Fredun Pharma Board Meeting/AGM

          • Fredun Pharma Dividends

          • Others
          • Meeting DateAnnounced onPurposeDetails
            Jul 29, 2024Jul 22, 2024Board MeetingQuarterly Results
            May 07, 2024Apr 24, 2024Board MeetingAudited Results & Final Dividend
            Feb 14, 2024Feb 05, 2024Board MeetingQuarterly Results
            Jan 18, 2024Dec 26, 2023AGME.G.M.
            Dec 16, 2023Dec 08, 2023Board MeetingOthers
          • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
            Final7%0.7Sep 22, 2023May 25, 2023
            Final7%0.7Sep 16, 2021Jun 29, 2021
            Final6%0.66Sep 18, 2020Jul 29, 2020
            Final7%0.7-May 08, 2024
            Final7%0.7-May 16, 2022

          • No other corporate actions details are available.

          About Fredun Pharma

          Fredun Pharmaceuticals Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 370.06 Crore) operating in Pharmaceuticals sector. Fredun Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023. Show More

          • Executives

          • Auditors

          • DN

            Daulat N Medhora

            Chairman & Jt. M. D
            FM

            Fredun Medhora

            Managing Director & CFO
            NM

            Nariman Medhora

            Non Executive Director
            AR

            Aspi Raimalwala

            Ind. Non-Executive Director
            Show More
          • Savla & Associates

          Industry

          Pharma - Indian

          Key Indices Listed on

          -

          Address

          URMI ESTATE,11th Floor,Ganpatrao Kadam Marg,Mumbai, Maharashtra - 400013

          Contact

          [email protected]

          http://www.fredungroup.com

          More Details

          Trending in Markets

          DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

          DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

          By using this site, you agree to the Terms of Service and Privacy Policy.

          Business News›Markets›Stocks›Stock Price Quotes›Fredun Pharma Share Price
          The Economic Times